Charles has over 25 years of experience with implantable medical devices with a diverse background in product development, regulatory approval and clinical trials, business development, and strategic planning. He currently serves as the Vice President of Clinical Affairs for Endologix. Prior to Endologix, Charles was the VP of Regulatory and Clinical Affairs and Compliance at the LVAD start-up CircuLite, Inc. Charles is principal consultant of Spot on Medical, a Santa Barbara based consulting firm focused on the medical device industry. He served as acting Vice President of Clinical Affairs for CoreValve prior to its acquisition by Medtronic, and subsequently served as an advisor to Medtronic’s Structural Heart division where he was involved with the Acquisition of ATS Medical and long range strategic planning matters. In addition to numerous consulting assignments, he has held full-time senior executive positions in both research and development and regulatory and clinical affairs for a number of venture-backed start-ups including Converge Medical, Ventracor, and nContact Surgical. He has also founded two cardiovascular device companies. Charles holds more the 24 patents, and has a degree in Biology from Westmont College.
Carter Meyer has been the Chief Executive Officer of Scientific Health Development since its formation in February 2006, and is a General Partner of its most recent fund. Prior to joining SHD, he was an attorney in private practice for over 12 years, most recently with the Dallas office of the Vinson & Elkins L.L.P. As an attorney, Mr. Meyer focused on commercial transactions with substantial experience buying, selling, financing and making investments in both public and private entities. Mr. Meyer has a B.B.A. in finance from Texas Christian University and a J.D. from St. Mary’s University School of Law. Mr. Meyer is a director of all SHD portfolio companies.
Jay joined De Novo Ventures in 2002 as a Managing Director. Prior to that, Jay was a co-founder of Origin Medsystems, a venture-funded medical technology start-up that was purchased by Eli Lilly & Company. When Eli Lilly divested its medical device businesses to form Guidant, he became a member of the corporation’s management committee. During this time, he served as president of numerous divisions, including the Minimally Invasive Surgery Group. In addition, Jay was the President of Compass, Guidant Corporation’s corporate business development and new ventures group. Prior to founding Origin, Jay held management positions in several start-ups, including Microgenics Corporation, and was a consultant with the international consulting firm of McKinsey & Company. He has been a member of the board of directors of several public companies, including Gynecare, Cardiogenesis, and Rita Medical. Jay received his MBA from Harvard University and his undergraduate degree from Stanford University. In addition to Loma Vista Medical, Jay sits on the boards of EBR Systems, PhotoThera, Pulmonx, Sierra Surgical and Synergeyes. He also represented De Novo on investments in Lumend and Hansen Medical.